Weill Cornell Medicine received a $1.5 million grant from the U.S. Department of Defense Prostate Cancer Research Program to develop new approaches for predicting the spread of cancer cells to the bone in men with prostate cancer, using tumor samples taken at early stages of the disease.
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis | Psychedelic Invest
–Human tissue study assessed SPU-21’s efficiency, optimization, and binding affinity– Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics
October 16, 2023